Vinge advises Active Biotech in relation to directed new share issue
April 04, 2013
In March this year, Active Biotech AB (publ) conducted a directed new share issue to Investor AB (publ) pursuant to which Active Biotech procured SEK 270 million.
Vinge’s team consisted of partner Erik Sjöman and associate Christian Lindhé.
Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
Vinge has represented Studsvik AB (publ) in connection with the acquisition of Kärnfull Next AB, a company developing methods for building small modular nuclear reactors.
